Does UPADACITINIB Cause Hyperthermia malignant? 8 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Hyperthermia malignant have been filed in association with UPADACITINIB (Rinvoq). This represents 0.0% of all adverse event reports for UPADACITINIB.
8
Reports of Hyperthermia malignant with UPADACITINIB
0.0%
of all UPADACITINIB reports
0
Deaths
6
Hospitalizations
How Dangerous Is Hyperthermia malignant From UPADACITINIB?
Of the 8 reports, 6 (75.0%) required hospitalization.
Is Hyperthermia malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for UPADACITINIB. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does UPADACITINIB Cause?
Pain (4,444)
Arthralgia (3,815)
Drug ineffective (3,384)
Covid-19 (2,978)
Rheumatoid arthritis (2,730)
Pain in extremity (2,353)
Fatigue (2,153)
Fall (2,081)
Surgery (2,037)
Therapy interrupted (1,741)
What Other Drugs Cause Hyperthermia malignant?
SUCCINYLCHOLINE (276)
SEVOFLURANE (207)
PROPOFOL (205)
FORANE (170)
ROCURONIUM (114)
FENTANYL (107)
SEVOFLURANE, USP (93)
ISOFLURANE (87)
MIDAZOLAM (62)
CISATRACURIUM (60)
Which UPADACITINIB Alternatives Have Lower Hyperthermia malignant Risk?
UPADACITINIB vs URAPIDIL
UPADACITINIB vs UREA
UPADACITINIB vs URIDINE TRIACETATE
UPADACITINIB vs UROFOLLITROPIN
UPADACITINIB vs URSODIOL